REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $480.05M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.70M
Average 1.24M
RGNX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
REGENXBIO Inc.NASDAQ: RGNX
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA turns negative
Q1 FY2026 EBITDA was -$77.49M, compared with $18.61M a year earlier. Trailing-twelve-month EBITDA was -$229.35M.
Context
- EBITDA amounted to 78.2% of revenue in FY2025, down 159.7 pp from a year earlier.
- EBITDA grew in size in 0 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 7 analysts of -$151.63M (-13.8%) for the fiscal year ending Dec 2026, a slowdown from the +32.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$77.49M-51.9% QoQ
- Last fiscal yearDec 2025
- -$133.26M+32.8% YoY
- LTMMar 2026
- -$229.35M-87.3% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -516.4% | +132.3% | +648.7 pp |
| 1 year | +32.8% | -13.8% | -46.6 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (133.26M) USD
- Year-over-year change
- +32.8%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (133.26M) | +32.8% |
| FY2024 | 2024-12-31 | (198.23M) | +17.2% |
| FY2023 | 2023-12-31 | (239.46M) | +2.0% |
| FY2022 | 2022-12-31 | (244.24M) | -237.9% |
| FY2021 | 2021-12-31 | 177.09M | — |
EBITDA vs competitors
How RGNX compares with its peers on the latest reported figures
- RGNX's LTM Mar 2026 EBITDA of -$229.35M is the lowest of the 10 companies compared; the peer median is -$129.14M.
- Its year-over-year change of -87.3% is the lowest of 10, against a peer median of +3.9%.
- EBITDA amounts to 261.2% of revenue for RGNX, versus a peer median of 246.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$64.18M | -19.1% | — | 1437.5% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$85.19M | +20.5% | — | — |
| LTM Mar 2026 | -$95.72M | +32.5% | — | 120.0% | |
| LTM Mar 2026 | -$112.54M | -37.5% | — | 308.4% | |
| LTM Mar 2026 | -$129.14M | +6.4% | — | 713.8% | |
| LTM Jun 2026 | -$143.84M | -16.8% | — | 167.8% | |
| LTM Mar 2026 | -$163.43M | +3.9% | — | 185.2% | |
| LTM Mar 2026 | -$190.1M | -38.9% | — | — | |
| LTM Mar 2026 | -$194.47M | +21.0% | — | — | |
| LTM Mar 2026 | -$229.35M | -87.3% | — | 261.2% | |
| Peer median (excluding RGNX) | -$129.14M | +3.9% | — | 246.8% | |
Competitors are the stored peer set for RGNX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 470.35M | 112.72M | 90.24M | 83.33M | 170.44M |
| Cost of Revenue | 51.83M | 54.55M | 37.21M | 33.57M | 20.3M |
| Gross Profit | 418.51M | 58.18M | 53.03M | 49.76M | 150.14M |
| Gross Margin | 89.0% | 51.6% | 58.8% | 59.7% | 88.1% |
| Research & Development | 181.44M | 242.45M | 232.27M | 208.52M | 228.3M |
| Selling, General & Admin | 79.33M | 85.28M | 88.49M | 76.62M | 82.86M |
| Operating Expenses | 258.53M | 321.06M | 321.16M | 283.11M | 311.34M |
| Depreciation & Amortization | 9.56M | 12.91M | 17.32M | 16.22M | 15.62M |
| EBITDA | 177.09M | (244.24M) | (239.46M) | (198.23M) | (133.26M) |
| EBITDA Margin | 37.7% | -216.7% | -265.4% | -237.9% | -78.2% |
| Operating Income | 159.98M | (262.88M) | (268.13M) | (233.35M) | (161.2M) |
| Operating Margin | 34.0% | -233.2% | -297.1% | -280.0% | -94.6% |
| Interest Income | 719K | 342K | 25K | 174K | 12.27M |
| Interest Expense | 26.28M | 23.25M | 6.86M | 12.66M | 45.01M |
| Other Income / Expenses | (18.73M) | (17.53M) | 4.48M | 6.24M | (32.68M) |
| Income Before Tax | 141.25M | (280.41M) | (263.65M) | (227.1M) | (193.88M) |
| Pre-Tax Margin | 30.0% | -248.8% | -292.2% | -272.5% | -113.8% |
| Income Tax Expense | 13.41M | (84K) | (152K) | 0 | 0 |
| Net Income | 127.84M | (280.32M) | (263.49M) | (227.1M) | (193.88M) |
| Net Margin | 27.2% | -248.7% | -292.0% | -272.5% | -113.8% |
| EPS (Basic) | 3.01 | (6.50) | (6.02) | (4.59) | (3.76) |
| EPS (Diluted) | 2.91 | (6.50) | (6.02) | (4.59) | (3.76) |
| Weighted Avg Shares | 42.44M | 43.15M | 43.73M | 49.51M | 51.57M |
| Weighted Avg Shares (Diluted) | 43.91M | 43.15M | 43.73M | 49.51M | 51.57M |
REGENXBIO Inc.
NASDAQ:RGNX
Intrinsic Alpha fair value
Locked
Current Price
$7.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.